Abstract 58P
Background
There is an increasing incidence of RC in the young. Clinicopathologic features are not clearly established especially in the local Filipino population. Moreover, treatment challenges occur in this population. This study aims to describe the clinicopathologic profile and outcomes in patients diagnosed with RC in the young at the Southern Philippines Medical Center, Adult Cancer Institute.
Methods
All RC patients were reviewed from January 2018 to December 2021. A total of 548 RC patients were reviewed retrospectively.
Results
A total of 99 patients were identified (18%) as RC in the young. Majority were males (68%) and have a family history of cancer (72%). Mean tumor distance was 4.82+6.0 cm from the anal verge. All patients had adenocarcinoma histology with 9% having mucinous component and 1% with signet ring features. For tumor differentiation, 56% had moderately and 23% had poorly differentiated tumors. Most patients were diagnosed with locally advanced disease (55% St IIIB, 12% St IIIC) and 24% with distant metastasis. Mean CEA levels were elevated (preoperative 59.44ng/ml and post-operative 49.42ng/ml). Among non-metastatic disease, most stage II and stage III RC patients received neoadjuvant long course chemoradiation (LCCRT) then Surgery then adjuvant chemotherapy (AC) (52%). Most common AC used was Capecitabine-Oxaliplatin. At the time of analysis, 57.6% had no evidence of disease while 38.4% progressed or metastasized to distant organs. In the overall population of RC in the young, median overall survival was 21.3 months (mos). Survival rate at 12 mos was 60% and at 24 mos was 40%.
Conclusions
RC in the young Filipino patient presented more with lower lying rectal tumors, moderately to poorly differentiated histology, and more advanced disease at diagnosis. Survival appeared to be worse compared to historical data. Improved understanding of this specific subgroup is necessary for better treatment options and outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
57P - V-set and immunoglobulin domain containing 1 (VSIG1): Gene vs protein expression in colorectal cancer tissue samples
Presenter: Simona Gurzu
Session: Poster viewing 02
59P - Platelet-derived growth factor (PDGF)-CC serum as clinical outcome predictor after six cycles of chemotherapy in colorectal cancer at RSMH Palembang
Presenter: Erty Sundarita
Session: Poster viewing 02
60P - Predictors of survival in stage III colorectal cancer patients treated with surgery and adjuvant chemotherapy: A single institution observational study
Presenter: Keng Man Chiang
Session: Poster viewing 02
61P - Can total neoadjuvant therapy in locally advanced rectal cancer replace standard treatment protocol?
Presenter: Ankita Mallick
Session: Poster viewing 02
62P - Chief complaints and baseline clinicopathological features of patients with colorectal cancer in a tertiary hospital in Yogyakarta Indonesia
Presenter: Yasjudan Putra
Session: Poster viewing 02
63P - Tumor sidedness and clinicopathological features of colorectal cancer in Medical Oncology Department, Yangon General Hospital: A retrospective review
Presenter: Thiri Tun
Session: Poster viewing 02
64P - Clinical profile and treatment outcome of patients with non-metastatic colon cancer: A single institutional study from India
Presenter: Sandip Ganguly
Session: Poster viewing 02
65P - Comparison of survival and recurrence pattern in Thai early stage colorectal cancer patients by tumor sidedness
Presenter: Chanchai Charonpongsuntorn
Session: Poster viewing 02
77P - Long-term outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: The FUGES-012 randomized clinical trial
Presenter: Qing Zhong
Session: Poster viewing 02